After pricing 12.5 million shares at $6 late this morning, ovarian cancer drug developer Endocyte opened for trading mid-day, with the stock initially gaining 7%. Endocyte, which is developing a treatment for platinum-resistant ovarian cancer, had originally planned to offer 5.35 million shares at a range of $13-$15, then changed the terms to 10.7 million shares at $7 before revising them again on Friday morning. RBC Capital Markets and Leerink Swann lead-managed the IPO.